Cipla Recalls Urinary Tract Infection Medication
The manufacturer initiated a voluntary recall after the drug failed to meet established impurity and degradation standards.
Updated on Oct. 15, 2026 in Consumer Goods
Live Poll
Do you trust that pharmaceutical companies are transparent when they initiate voluntary drug recalls?
Cipla has issued a voluntary recall for its Fosfomycin Tromethamine Granules for Oral Solution in the United States. The product is used to treat acute uncomplicated urinary tract infections in women.
Why it matters
The medication was pulled from the market because it failed to comply with required safety standards for impurity and degradation. While the risk of serious health complications is considered remote, the recall ensures that substandard medicine does not reach patients.
The US FDA assigned a Class II recall designation to the product, a classification for goods that may cause temporary or reversible health consequences. This status is distinct from more severe recall categories that pose a high risk of serious injury.
The players
Cipla
Cipla is a multinational pharmaceutical company headquartered in New Delhi, India, that manufactures a wide range of generic and proprietary drugs.
US FDA
The US FDA is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of drugs and medical devices.
The details
The recall specifically targets Fosfomycin Tromethamine Granules for Oral Solution, which fell short of quality benchmarks regarding chemical purity. The company is working through the regulatory process to manage the removal of the affected product batches.
Timeline
October 15, 2026: The voluntary drug recall was reported.
Market Landscape
This recall aligns with the FDA's Class II recall protocols, which categorize the urgency of product removals based on the severity of potential health risks. Such measures serve as a critical component of the regulatory framework designed to maintain the integrity of the pharmaceutical supply chain.
Patients currently prescribed this medication should consult with their healthcare provider to verify if their specific supply is part of the recall. Individuals may need to secure alternative treatments to ensure the continued management of urinary tract infections.
The takeaway
Patients should always verify with their pharmacy if they possess any recalled medication. Maintaining open communication with healthcare professionals is essential when sudden changes occur in the availability of prescribed treatments.
Further reading
For additional updates on product safety and industry standards, visit the Consumer Goods section.
Source note: This article includes information reported by ETPharma.
Live Poll
Do you trust that pharmaceutical companies are transparent when they initiate voluntary drug recalls?
